Affiliation
Angela Lamarca, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom.Issue Date
2014-06-28
Metadata
Show full item recordAbstract
Pancreatic ductal adenocarcinoma (PDA) is known for its poor prognosis. Most of the patients are diagnosed with advanced stages, when no curative treatment is available. Currently, despite extensive clinical research on PDA, the median overall survival remains short. Diagnosis delay and primary chemo-resistance due to its intrinsic biological nature may explain the challenges to improve our results. Our knowledge about the molecular biology of PDA has exponentially increased during the last decades and its use for the development of biomarkers could help to reach better results in the clinical setting. These biomarkers could be the clue for the improvement in PDA clinical research by earlier detection strategies with diagnostic biomarkers, and by an individualization of treatment approach with prognostic and predictive biomarkers. This review summarizes the current knowledge about the molecular biology of PDA and the status of the most important prognostic and predictive biomarkers.Citation
Pancreatic biomarkers: Could they be the answer? 2014, 20 (24):7819-7829 World J GastroenterolJournal
World Journal of GastroenterologyDOI
10.3748/wjg.v20.i24.7819PubMed ID
24976720Type
ArticleLanguage
enISSN
2219-2840ae974a485f413a2113503eed53cd6c53
10.3748/wjg.v20.i24.7819